Sigma Healthcare Chooses A Smaller UK Bet Over Boots

Fund managers split on valuation even as the Chemist Warehouse owner opts for a measured joint venture over a transformational acquisition

30 Jun 2026 · 7 min read

A brief flirtation with a much larger deal tested investor confidence in Sigma Healthcare in June 2026. Pendal Group reported the stock fell 9.6 per cent on reports the Chemist Warehouse owner was evaluating a bid for UK chemist chain Boots, a move it viewed as high-risk and dilutive for returns. Hyperion Asset Management confirmed the company engaged in preliminary discussions on 10 June before the board withdrew its interest just five days later, concluding a Boots acquisition would not currently meet its strategic and capital investment objectives, a decision the manager called a rational and disciplined outcome given a transformational global acquisition would materially increase execution risk where organic growth opportunities already looked substantial.

Managers split sharply on how to read the episode. Ten Cap called Sigma its top buy idea in June 2026, arguing the share price weakness around the Boots reports created an attractive opportunity, particularly once the company walked away, reinforcing that management is not chasing offshore scale at any price. Alvia Asset Partners took the opposite view, issuing a sell recommendation and arguing that even considering the roughly A$15 billion Boots acquisition highlighted the scale and risk of the company's international ambitions, warning that history shows companies reaching for growth abroad are often facing challenges at home.

The market has been too focused on the Boots noise and not enough on the domestic growth runway. SIG offers defensive demand, structural growth and execution upside.

— Ten Cap, Article, June 2026

A more measured path into the UK

Rather than a large acquisition, Sigma has instead pursued a capital-light UK entry. Hyperion Asset Management detailed a memorandum of understanding announced 5 June 2026 under which Sigma will acquire a 75 per cent interest in a joint venture with Greenlight Healthcare, an employee-owned, 22-store London pharmacy group, licensing the Chemist Warehouse brand and providing retail support while Greenlight contributes dispensary services and existing NHS relationships. Pendal Group's earlier May 2026 update had already flagged this deal, noting the initial rollout would be a slow process with likely no financial benefit for over five years, since Greenlight itself is loss-making and financially distressed and the deal is mainly about accessing licences to open new stores.

The operational engine behind the international ambitions

What underpins the confidence to even consider offshore expansion is a genuinely strong domestic business. Hyperion Asset Management's February 2026 half-year update showed group sales up 14.9 per cent, with Chemist Warehouse Australian network sales up 17.2 per cent and international sales up 24.5 per cent, both materially outpacing the market, alongside like-for-like sales growth of 15.0 per cent domestically. The manager said management reiterated its long-term Australian franchise network targets of 900 Chemist Warehouse stores, 300 Amcal stores and 150 Discount Drug Stores, implying a substantial rollout runway still ahead, with domestic sales growth running at 16.7 per cent for the ten months to April 2026.

Chemist Warehouse is a 'category killer' with material growth potential remaining in both Australia and internationally. This positions Chemist Warehouse for sustained double-digit growth and continued market share gains.

— Hyperion Asset Management, Monthly Report, September 2025

Greencape Capital's December 2025 quarterly report added on-the-ground detail from a tour of stores in Dubai, Auckland and Dublin, noting the consistency of the retail experience across markets was immediately apparent, and that incumbent pharmacy operators in the Gulf region typically run much smaller stores than Chemist Warehouse's format, presenting what it saw as a clear opportunity for a significant network rollout across the Middle East, even with only two stores operating there at the time.

A valuation debate that predates the Boots episode

Even before the Boots reports, managers disagreed sharply on valuation. Alliance Bernstein called Sigma an outright sell in May 2026, noting the stock traded on 50 times earnings for a business selling perfumes and pharmaceuticals, and drew a parallel between the company's reverse-merger structure and a traditional IPO, where every incentive points toward hitting growth numbers for 18 to 24 months before a hot-potato dynamic can set in. Paradice Investment Management took a more balanced middle ground, rating the stock a hold, saying it liked the Chemist Warehouse powerhouse and its mid-teens like-for-like growth, probably the best retailer in Australia, but wanted to see accelerated store rollout and profitable international scale before adding further, arguing some of the opportunity was already captured in the price.

What managers are watching next

With the Greenlight joint venture's first phase focused on rebranding up to five existing London stores and a decision on broader rollout subject to performance, the key questions for managers are whether that measured UK pathway proves the concept without the execution risk a full-scale Boots acquisition would have carried, and whether Sigma's GLP-1-driven pharmacy foot traffic and domestic store rollout targets continue to justify a premium multiple that bears like Alliance Bernstein believe the market has yet to properly stress-test.